W. Koek

2 papers in the library · publishing 1988-2020

Papers

Serotonin Transporter and Plasma Membrane Monoamine Transporter Are Necessary for the Antidepressant-Like Effects of Ketamine in Mice

International Journal of Molecular Sciences October 1, 2020 M. Bowman, M. Vitela, K. Clarke et al.

Ketamine rapidly inhibits the clearance of serotonin from the hippocampus in mice, an effect that depends on the serotonin transporter (SERT) and the plasma membrane monoamine transporter (PMAT). In mice lacking either SERT or PMAT, ketamine no longer slows serotonin clearance and fails to produce antidepressant-like effects in the forced swim test. The findings suggest that ketamine's ability to block serotonin reuptake via both transporters may contribute to its rapid antidepressant action, alongside its known NMDA receptor antagonism. This work may guide development of depression treatments with fewer side effects than ketamine.

DOI: 10.3390/ijms21207581 Full text Medicine Biology

MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys.

Journal of Pharmacology and Experimental Therapeutics June 1, 1988 W. Koek, James H Woods, G. Winger

MK-801, a proposed NMDA antagonist, produced behavioral effects in pigeons, rats, and rhesus monkeys that closely resembled those of phencyclidine (PCP), including catalepsy, discriminative stimulus effects, locomotion, sniffing, positive reinforcing effects, and anesthesia without eye closure or respiratory depression. MK-801 was 2 to 10 times more potent than PCP depending on the species and effect measured. These findings support the hypothesis that certain PCP-like behavioral effects may result from reduced neurotransmission at NMDA-preferring receptors. The behavioral similarities suggest that clinical trials of MK-801 should evaluate PCP-like activity.

DOI: 10.1016/s0022-3565(25)24082-4 Medicine Psychology